|Institutional Source||Beutler Lab|
|Synonyms||presynaptic cytomatrix protein|
|Is this an essential gene?||Possibly non essential (E-score: 0.439)|
|Stock #||R1946 (G1)|
|Chromosomal Location||108096022-108190384 bp(-) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||A to G at 108114651 bp|
|Amino Acid Change||Phenylalanine to Leucine at position 1301 (F1301L)|
|Ref Sequence||ENSEMBL: ENSMUSP00000035208 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000035208]|
|Predicted Effect||probably damaging
AA Change: F1301L
PolyPhen 2 Score 0.988 (Sensitivity: 0.73; Specificity: 0.96)
AA Change: F1301L
|Predicted Effect||probably benign
|Coding Region Coverage||
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] Neurotransmitters are released from a specific site in the axon terminal called the active zone, which is composed of synaptic vesicles and a meshwork of cytoskeleton underlying the plasma membrane. The protein encoded by this gene is thought to be a scaffolding protein involved in organizing the presynaptic cytoskeleton. The gene is expressed primarily in neurons in the brain. A similar gene product in rodents is concentrated in the active zone of axon terminals and tightly associated with cytoskeletal structures, and is essential for regulating neurotransmitter release from a subset of synapses. [provided by RefSeq, Jul 2008]
PHENOTYPE: Mutants lacking functional protein exhibit impaired hippocampal and photoreceptor synaptic transmission, aberrant photoreceptor ribbon synapse formation, and spontaneous epileptic seizures. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Bsn||
(F):5'- AGCTTGAGAGGATCCTGAGG -3'
(R):5'- AGGGCTCCTTTGAATATCAAGAC -3'
(F):5'- CTGAGGCTCTTTTGCAAAATGC -3'
(R):5'- TCCTTTGAATATCAAGACACCCAAG -3'